JP3815496B2 - 酢酸アニリド誘導体を有効成分とする過活動膀胱治療剤 - Google Patents

酢酸アニリド誘導体を有効成分とする過活動膀胱治療剤 Download PDF

Info

Publication number
JP3815496B2
JP3815496B2 JP2004549600A JP2004549600A JP3815496B2 JP 3815496 B2 JP3815496 B2 JP 3815496B2 JP 2004549600 A JP2004549600 A JP 2004549600A JP 2004549600 A JP2004549600 A JP 2004549600A JP 3815496 B2 JP3815496 B2 JP 3815496B2
Authority
JP
Japan
Prior art keywords
bladder
therapeutic agent
overactive bladder
active ingredient
test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2004549600A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2004041276A1 (ja
Inventor
俊行 高須
修一 佐藤
政志 鵜飼
龍也 丸山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32310425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP3815496(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of JPWO2004041276A1 publication Critical patent/JPWO2004041276A1/ja
Application granted granted Critical
Publication of JP3815496B2 publication Critical patent/JP3815496B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2004549600A 2002-11-07 2003-11-04 酢酸アニリド誘導体を有効成分とする過活動膀胱治療剤 Expired - Lifetime JP3815496B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002323792 2002-11-07
JP2002323792 2002-11-07
PCT/JP2003/014065 WO2004041276A1 (ja) 2002-11-07 2003-11-04 酢酸アニリド誘導体を有効成分とする過活動膀胱治療剤

Publications (2)

Publication Number Publication Date
JPWO2004041276A1 JPWO2004041276A1 (ja) 2006-03-02
JP3815496B2 true JP3815496B2 (ja) 2006-08-30

Family

ID=32310425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004549600A Expired - Lifetime JP3815496B2 (ja) 2002-11-07 2003-11-04 酢酸アニリド誘導体を有効成分とする過活動膀胱治療剤

Country Status (28)

Country Link
US (5) US7750029B2 (enExample)
EP (1) EP1559427B1 (enExample)
JP (1) JP3815496B2 (enExample)
KR (1) KR100967070B1 (enExample)
CN (1) CN100406011C (enExample)
AT (1) ATE500827T1 (enExample)
AU (1) AU2003284700B2 (enExample)
BE (1) BE2013C040I2 (enExample)
BR (1) BR0316080A (enExample)
CA (1) CA2503570C (enExample)
CY (2) CY1111399T1 (enExample)
DE (1) DE60336334D1 (enExample)
DK (1) DK1559427T3 (enExample)
ES (1) ES2360353T3 (enExample)
FR (1) FR13C0032I2 (enExample)
HU (1) HUS1300027I1 (enExample)
IL (1) IL168121A (enExample)
LU (1) LU92218I2 (enExample)
MX (1) MXPA05004925A (enExample)
NL (1) NL300599I2 (enExample)
NO (2) NO334948B1 (enExample)
NZ (1) NZ539577A (enExample)
PL (1) PL211687B1 (enExample)
PT (1) PT1559427E (enExample)
RU (1) RU2321401C2 (enExample)
SI (1) SI1559427T1 (enExample)
WO (1) WO2004041276A1 (enExample)
ZA (1) ZA200503510B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10842780B2 (en) 2008-09-30 2020-11-24 Astellas Pharma Inc. Pharmaceutical composition for modified release
US11707451B2 (en) 2010-03-29 2023-07-25 Astellas Pharma Inc. Pharmaceutical composition for modified release
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10351271A1 (de) * 2003-10-31 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung der Stressinkontinenz und/oder Mischinkontinenz
SI2216021T1 (sl) * 2007-11-02 2013-01-31 Astellas Pharma Inc. Farmacevtski sestavek za zdravljenje prekomerno aktivnega sečnega mehurja
EP2223690A4 (en) * 2007-12-21 2011-02-23 Astellas Pharma Inc PHARMACEUTICAL COMPOSITION FOR THE REDUCTION OF LOWER HARNESS SYMPTOMS
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
WO2010053068A1 (ja) * 2008-11-07 2010-05-14 大日本住友製薬株式会社 新規で有用な下部尿路症状治療剤
WO2010147830A2 (en) * 2009-06-15 2010-12-23 Auspex Pharmaceuticals, Inc. Aminothiazole modulators of beta-3-adrenoreceptor
JP5849946B2 (ja) * 2010-03-29 2016-02-03 アステラス製薬株式会社 放出制御医薬組成物
US9655885B2 (en) 2011-05-18 2017-05-23 Dr. Reddy's Laboratories Ltd. Amorphous mirabegron and processes for crystal forms of mirabegron
IN2013CN09704A (enExample) 2011-05-18 2015-07-03 Reddys Lab Ltd Dr
EP2832730A4 (en) 2012-03-30 2015-09-09 Astellas Pharma Inc MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
TW201424772A (zh) 2012-08-31 2014-07-01 Astellas Pharma Inc 經口投與用醫藥組成物
WO2014132270A2 (en) * 2013-02-27 2014-09-04 Msn Laboratories Limited Process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-{[(2r)-2-hydroxy-2-phenyl ethyl]amino}ethyl)phenyl]acetamide monohydrochloride, its intermediates and polymorph thereof
CN103193730A (zh) * 2013-04-17 2013-07-10 苏州永健生物医药有限公司 一种米拉贝隆的合成方法
CN103193658A (zh) * 2013-04-18 2013-07-10 苏州永健生物医药有限公司 一种（r）-2-对硝基苯乙胺基-1-苯乙醇及其盐的合成方法
CN103232368B (zh) * 2013-04-18 2015-08-12 苏州永健生物医药有限公司 一种(r)-4-硝基苯乙基-(2-羟基-2-苯乙基)-氨基甲酸叔丁酯的合成方法
CN103232352B (zh) * 2013-05-11 2015-12-23 苏州永健生物医药有限公司 (r)-4-(2-(2-羟基-2-苯乙胺基)乙基)苯胺基甲酸叔丁基酯
CN105579057A (zh) * 2013-07-23 2016-05-11 阿勒根公司 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物
ITMI20131653A1 (it) * 2013-10-07 2015-04-08 Dipharma Francis Srl Forme cristalline di un agonista adrenergico
RU2550968C1 (ru) * 2013-11-29 2015-05-20 Федеральное государственное бюджетное учреждение "Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Комплексный способ лечения пациенток с хроническими рецидивирующими циститами и рефрактерным гиперактивным мочевым пузырем
WO2015155664A1 (en) * 2014-04-08 2015-10-15 Suven Life Sciences Limited An improved process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-[[(2r)-2-hydroxy-2- phenylethyl]amino]-ethyl)phenyl]acetamide
WO2015162536A1 (en) * 2014-04-22 2015-10-29 Calyx Chemicals And Pharmaceuticals Ltd. Novel process for preparation of mirabegron and it's intermediate
CN104016943A (zh) * 2014-05-23 2014-09-03 苏州凯瑞医药科技有限公司 一种米拉贝隆的合成方法
CN104016877B (zh) * 2014-06-13 2017-02-15 南京海融制药有限公司 一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用
CN104230840A (zh) * 2014-09-05 2014-12-24 安徽联创药物化学有限公司 米拉贝隆的合成方法
CA2967390A1 (en) 2014-11-20 2016-05-26 Allergan, Inc. Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist
CN104496841B (zh) * 2014-11-26 2017-01-25 南京工业大学 一种米拉贝隆中间体的合成方法
CN104744292A (zh) * 2015-03-11 2015-07-01 南京工业大学 (r)-2-((4-硝基苯乙基)氨基)-2-氧代-1-苯乙基乙酸酯或其衍生物的制备方法
JP2018090490A (ja) 2015-03-31 2018-06-14 アステラス製薬株式会社 ミラベグロン含有医薬組成物
JP6618736B2 (ja) 2015-09-01 2019-12-11 沢井製薬株式会社 ミラベグロン含有錠剤、ミラベグロン含有製剤の製造方法及びミラベグロン含有造粒物の製造方法
CN106278909B (zh) * 2016-08-12 2022-07-15 浙江华海药业股份有限公司 一种米拉贝隆中间体的后处理方法
EP3360866B1 (en) 2017-02-14 2019-01-02 Alfred E. Tiefenbacher (GmbH & Co. KG) Mirabegron prodrugs
KR102051132B1 (ko) * 2017-03-17 2019-12-02 주식회사 종근당 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물
KR101868438B1 (ko) 2017-04-13 2018-06-20 (주) 성운파마코피아 아미드 유도체의 제조방법
EP3636256B1 (en) 2017-05-31 2024-07-03 SBI Pharmaceuticals Co., Ltd. Prophylactic or therapeutic agent for hyperactive bladder
KR20250099259A (ko) 2017-06-06 2025-07-01 유로반트 사이언시즈 게엠베하 과민성 방광의 치료를 위한 비베그론의 용도
KR102398639B1 (ko) 2017-06-20 2022-05-17 (주) 성운파마코피아 아미드 유도체의 염 및 그 제조방법
KR101937713B1 (ko) 2017-07-14 2019-01-14 주식회사 대웅제약 약제학적 제제 및 그 제조방법
WO2019013583A2 (ko) 2017-07-14 2019-01-17 주식회사 대웅제약 약제학적 제제 및 그 제조방법
TW202038963A (zh) 2018-12-05 2020-11-01 瑞士商優洛凡特科學公司 維貝隆（ｖｉｂｅｇｒｏｎ）於治療患有良性前列腺增生之男性中膀胱過動症症狀之用途
KR20200117091A (ko) 2019-04-02 2020-10-14 제이투에이치바이오텍 (주) 미라베그론 전구체 약물 화합물 및 이의 과민성 방광 질환의 치료 또는 개선을 위한 의약 용도
EP3722285B1 (en) 2020-04-08 2022-03-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Process for preparing mirabegron enacarbil
CN113816864B (zh) * 2020-06-18 2024-03-29 南京正大天晴制药有限公司 一种(r)-2-羟基-n-[2-(4-氨基苯基)乙基]-2-苯乙胺的制备方法
KR20220081033A (ko) 2020-12-08 2022-06-15 주식회사 한서켐 미라베그론 α형 결정의 제조방법
EP4338729A1 (en) 2022-09-19 2024-03-20 Sanovel Ilac Sanayi Ve Ticaret A.S. A tablet comprising mirabegron
EP4410279A1 (en) 2023-01-25 2024-08-07 Sanovel Ilac Sanayi Ve Ticaret A.S. A film tablet comprising mirabegron
KR20240171516A (ko) 2023-05-30 2024-12-09 주식회사 디앤아이바이오 미라베그론 서방정
TR2024008630A1 (tr) 2024-07-04 2026-01-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Mi̇rabegron i̇çeren modi̇fi̇ye salimli bi̇r tablet bi̇leşi̇mi̇
WO2026064392A1 (en) 2024-09-17 2026-03-26 Flavostar Llc Fixed dose combination of flavoxate and beta-3 adrenergic receptor agonists, and formulations and manufacturing processes thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07119189B2 (ja) 1989-09-28 1995-12-20 北陸製薬株式会社 光学活性なベンジルアルコール誘導体及びその用途
GB9107827D0 (en) 1991-04-12 1991-05-29 Fujisawa Pharmaceutical Co New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
IL104567A (en) 1992-02-03 1997-03-18 Fujisawa Pharmaceutical Co Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
JPH06293664A (ja) 1993-04-05 1994-10-21 Fujisawa Pharmaceut Co Ltd β３−アドレナリン作動薬の新規医薬用途
AU6581294A (en) 1993-04-26 1994-11-21 Fujisawa Pharmaceutical Co., Ltd. Ethanolamine derivatives useful for the treatment of gastrointestinal disorders
JPH07228543A (ja) 1994-02-16 1995-08-29 Fujisawa Pharmaceut Co Ltd β３−アドレナリン作動薬の新規医薬用途
CZ126598A3 (cs) 1995-10-26 1998-09-16 Mitsubishi-Tokyo Pharmaceuticals, Inc. Fenylethanolaminové sloučeniny, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
EP0932401A1 (en) * 1996-07-01 1999-08-04 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
CA2263659A1 (en) 1996-08-19 1998-02-26 Kissei Pharmaceutical Co., Ltd. Preventive/remedy for frequent urination and urinary incontinence
CA2302496C (en) * 1997-08-28 2009-12-08 Mount Cook Biosciences, Inc. Urinary incontinence therapy
KR100506568B1 (ko) 1997-10-17 2006-04-21 아스텔라스세이야쿠 가부시키가이샤 아미드유도체및이의염,및이를포함하는약제학적제제
ATE250570T1 (de) 1997-12-18 2003-10-15 Kissei Pharmaceutical Phenylaminoalkylcarbonsäure-derivate und medizinische zusammensetzungen, die diese enthalten
ATE275126T1 (de) * 1998-04-14 2004-09-15 Kissei Pharmaceutical 2-methylpropionsäure-derivate und sie enthaltende medizinische zubereitungen
MY126489A (en) 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
CA2362586A1 (en) * 1999-02-12 2000-08-17 Genset S.A. Biallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism
GB2356197A (en) 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
JP2001114736A (ja) * 1999-10-19 2001-04-24 Kissei Pharmaceut Co Ltd ２−アミノプロパノール誘導体
EP1258253A1 (en) 2000-01-28 2002-11-20 Asahi Kasei Kabushiki Kaisha Novel remedies with the use of beta3 agonist
AUPQ585000A0 (en) * 2000-02-28 2000-03-16 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
AR035605A1 (es) * 2000-12-11 2004-06-16 Bayer Corp Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
US7342117B2 (en) 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
EP1879578A4 (en) * 2005-03-21 2009-05-13 Dov Pharmaceutical Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10842780B2 (en) 2008-09-30 2020-11-24 Astellas Pharma Inc. Pharmaceutical composition for modified release
US12059409B1 (en) 2008-09-30 2024-08-13 Astellas Pharma Inc. Pharmaceutical composition for modified release
US11707451B2 (en) 2010-03-29 2023-07-25 Astellas Pharma Inc. Pharmaceutical composition for modified release
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Also Published As

Publication number Publication date
NZ539577A (en) 2007-06-29
USRE44872E1 (en) 2014-04-29
CY1111399T1 (el) 2015-08-05
NO20052691D0 (no) 2005-06-06
PT1559427E (pt) 2011-05-27
RU2321401C2 (ru) 2008-04-10
NO2015001I1 (no) 2015-01-19
KR20050072809A (ko) 2005-07-12
LU92218I9 (enExample) 2019-01-17
BE2013C040I2 (enExample) 2023-03-07
CY2013023I1 (el) 2015-10-07
IL168121A (en) 2011-12-29
CY2013023I2 (el) 2015-10-07
JPWO2004041276A1 (ja) 2006-03-02
HUS1300027I1 (hu) 2016-08-29
DK1559427T3 (da) 2011-04-26
NO334948B1 (no) 2014-08-04
US20110230530A1 (en) 2011-09-22
PL376771A1 (pl) 2006-01-09
NO2015001I2 (no) 2015-01-26
RU2005117367A (ru) 2006-01-20
LU92218I2 (fr) 2014-01-07
PL211687B1 (pl) 2012-06-29
DE60336334D1 (de) 2011-04-21
WO2004041276A1 (ja) 2004-05-21
EP1559427A1 (en) 2005-08-03
FR13C0032I1 (enExample) 2013-08-09
AU2003284700B2 (en) 2009-05-28
MXPA05004925A (es) 2005-08-18
KR100967070B1 (ko) 2010-07-01
US7750029B2 (en) 2010-07-06
NL300599I2 (enExample) 2017-01-03
ES2360353T3 (es) 2011-06-03
NO20052691L (no) 2005-07-15
CA2503570A1 (en) 2004-05-21
CN100406011C (zh) 2008-07-30
US8835474B2 (en) 2014-09-16
BR0316080A (pt) 2005-09-27
EP1559427B1 (en) 2011-03-09
CA2503570C (en) 2011-04-19
CN1711085A (zh) 2005-12-21
EP1559427A4 (en) 2007-05-30
US20090093529A1 (en) 2009-04-09
SI1559427T1 (sl) 2011-06-30
FR13C0032I2 (fr) 2014-03-07
ATE500827T1 (de) 2011-03-15
ZA200503510B (en) 2006-12-27
AU2003284700A1 (en) 2004-06-07
US20060115540A1 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
JPWO2004041276A1 (ja) 酢酸アニリド誘導体を有効成分とする過活動膀胱治療剤
EP3506900B1 (en) Ampreloxetine for use in the treatment of neurogenic orthostatic hypotension
JPH10130144A (ja) アルツハイマー病の治療および予防用の医薬を製造するための非ペプチドのブラジキニンアンタゴニストの使用
JP2026504208A (ja) ベンゾイソチアゾール化合物、その医薬組成物および用途
US6329407B1 (en) Use of polycyclic thiazole systems for the treatment of obesity
JP7569953B2 (ja) Ｓｓｔｒ４アゴニスト及びその塩の調製のための方法並びに使用のための用量レジメン
US9629833B2 (en) Bitopic muscarinic agonists and antagonists and methods of synthesis and use thereof
EP2851073B1 (en) Prophylactic agent and/or therapeutic agent for stress urinary incontinence
CN109422751A (zh) 一类具有降解酪氨酸蛋白激酶jak3活性的化合物
EP1341777B1 (en) 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatement of incontinence
CN115960135B (zh) 抗组胺类化合物及其制备方法和用途
HK40121263A (en) Compound for use in the treatment of neurogenic orthostatic hypotension
WO2007123126A1 (ja) 慢性心不全における運動耐容能低下の改善剤
HK40008873A (en) Ampreloxetine for use in the treatment of neurogenic orthostatic hypotension
HK40008873B (en) Ampreloxetine for use in the treatment of neurogenic orthostatic hypotension
JPWO2006077846A1 (ja) 注意欠陥／多動性障害治療薬
JPWO2003097060A1 (ja) トロポロン誘導体を用いた経口投与用頻尿・尿失禁の治療剤又は予防剤若しくは経口投与用睡眠導入剤

Legal Events

Date Code Title Description
A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20051209

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20060104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060131

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20060516

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20060529

R150 Certificate of patent or registration of utility model

Ref document number: 3815496

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100616

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100616

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110616

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120616

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120616

Year of fee payment: 6

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120616

Year of fee payment: 6

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120616

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120616

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130616

Year of fee payment: 7

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130616

Year of fee payment: 7

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130616

Year of fee payment: 7

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250